Gilead Sciences

Gilead Sciences is a US-based biopharmaceutical company. It is currently newsworthy due to its strategic acquisition of Ouro Medicines for up to $2.18 billion. This acquisition grants Gilead access to an antibody-based medicine for autoimmune diseases, originally licensed from China's Keymed Biosciences. This move is part of a broader trend among global drug manufacturers, including Gilead, to bolster their drug pipelines through mergers, acquisitions, and licensing deals in the face of upcoming patent expirations. Furthermore, Gilead Sciences is also relevant due to its participation in recent agreements with the US government, alongside companies like Bristol Myers Squibb and Merck, to lower prescription drug prices in the United States. These developments highlight Gilead's efforts to both expand its product portfolio and address concerns regarding drug affordability.